This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

Home

Recommendations

SOGC Recommendations

NACI Recommendations

CIQ Recommendations

About RSV

About RSV

Infants at Risk

Individuals ≥ 60 Years of Age

About ABRYSVO

Reconstitution and Storage

Dosing and Administration

Mechanism of Action

Efficacy and Safety Profiles

Clinical Trials

MATISSE Study Design

MATISSE Data

MATISSE Safety Profile

RENOIR Study Design

RENOIR Data

RENOIR Safety Profile

More

Coverage Information

Patient Profiles

FAQ

Resources

Product MonographSafety Information
Pfizer Respiratory Vaccine Portfolio
Recommendations from NACIRSVpreF is included as an option in the NACI statement on the prevention of RSV disease in older adults1

NACI recommends:

  • RSV immunization programs for adults 75 years of age and older, particularly for older adults at increased risk of severe RSV disease.
  • RSV immunization programs for adults 60 years of age and older who are residents of nursing homes and other chronic care facilities.
  • That immunization with an RSV vaccine may be considered as an individual decision by adults 60 to 74 years of age with their healthcare provider.
To see the complete statement, click here.To see the complete statement,
click here.NACI: National Advisory Committee on Immunization; RSV: respiratory syncytial virus; RSVpreF: respiratory syncytial virus prefusion F

NACI: National Advisory Committee on Immunization; RSV: respiratory syncytial virus; RSVpreF: respiratory syncytial virus prefusion F

Reference:Statement on the prevention of respiratory syncytial virus (RSV) disease in older adults. National Advisory Committee on Immunization (NACI). July 2024.RecommendationsAbout RSV

Learn more about respiratory syncytial virus and its impact on high-risk populations.

PP-A1G-CAN-0117-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN
Are you a resident of Quebec?